Immunotherapy first for lung cancer too large for initial surgery or radiation
Follows adults with advanced lung cancer given immunotherapy before further treatment.
Plain-language title generated from the registry record
Registry title: Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option
Key facts
- Where
- Esslingen am Neckar, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with newly diagnosed non-small cell lung cancer, where surgery or full chemo-radiotherapy cannot be done first. They receive immunotherapy and are then re-evaluated.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Non-small cell lung cancer proven by tissue or cell tests, stage III to IVA (oligometastatic, meaning few spread sites), staged completely
- Earlier treatment
- Newly diagnosed. Surgery or definitive chemo-radiotherapy as first treatment must not be possible.
Main reasons for not taking part
- Tumor can be removed by surgery first
- Definitive chemo-radiotherapy can be given first
Read by machine on 12 November 2026.
Where in Germany
- Klinikum EsslingenEsslingen am Neckar, GermanyContact: Annika LandmesserTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Klinikum Esslingen
- Trial code
- NCT04926584
- Record updated
- 16 August 2022
- Original description
In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.Read full original descriptionShow less
Prospective Trial of Immunotherapy Prior to Resection, Definitive Chemo-radiotherapy, or Palliative Therapy in Patients With Locally Advanced or Oligometastatic Non-small Cell Lung Cancer Without a Primary Curative Option
In a certified lung- cancer center, patients with NSCLC and a potentially curative stage (including patients with oligometastatic disease) are prospectively enrolled if curative treatment (either definitive radio-chemotherapy or resection) cannot be performed due to large tumor size or for functional reasons. For these patients, the multidisciplinary tumor board (MDB) recommends immuno-(chemo)therapy and re-evaluation. Response is assessed radiologically including PET-CT if indicated. After review of the MDB, patients receive either definitive curative treatment or palliative treatment.
Inclusion: newly diagnosed NSCLC; histologically or cytologically proven; stage III - IVA (oligometastatic) by complete staging; ECOG 0-2; life expectancy 3 months; ability to provide written informed consent.
Exclusion: primary resectability; primary definitive chemoradiotherapy feasible.